Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review.

Marshall, Gary S; Fergie, Jaime; Presa, Jessica; Peyrani, Paula

Marshall, Gary S; Fergie, Jaime; Presa, Jessica; Peyrani, Paula.

Afiliação

Marshall GS; Division of Pediatric Infectious Diseases, Norton Children's and University of Louisville School of Medicine, 571 S. Floyd St, Suite 321, Louisville, KY, 40202, USA. gary.marshall@louisville.edu.
Fergie J; Driscoll Children's Hospital, Corpus Christi, TX, USA.
Presa J; Vaccines Medical Development & Scientific/Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.
Peyrani P; Vaccines Medical Development & Scientific/Clinical Affairs, Pfizer Inc, Collegeville, PA, USA.

Infect Dis Ther ; 11(3): 937-951, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35357651

Palavras-chave

Adolescents; Infants; Invasive meningococcal disease; Meningococcal conjugate vaccine; Neisseria meningitidis; Pentavalent

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Infect Dis Ther Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google